The Canadian EMBOLDEN I trial was a large randomized, double-blind trial comparing quetiapine (300 or 600 mg/day), lithium (600-1800 mg/day) or placebo in 802 patients with bipolar I or II disorder (Young et al. J Clin Psychiatry 2010; 71:150-162). The primary endpoint was the change from baseline to week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) total score.